The Lineberger Comprehensive Cancer Center is slated to lead a clinical trial testing a new option for colorectal cancer patients whose illness has not subsided after first-line treatments.
About 40 percent of patients whose cancers contain certain mutant genes see their illnesses progress in spite of traditional primary treatments.
Dr. Richard Goldberg, associate director for clinical research at the Lineberger Cancer Center, is the trial’s principal investigator.
The study is sponsored financially by Bayer HealthCare AG, which will provide the medication free to patients involved in the trial.
It will begin this month and will involve 240 patients at the University and at other sites throughout North Carolina.
